Sttr phase II - patterned, responsive cellular therapies using novel mammalian cellular regulator systems
Ended Definitive Contract Awarded Last action
- Contract number
- HR001121C0142
- Awardee
-
General Biologics Inc. UEI YX34DPZHLJN5
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Obligated
- $500,000
Award facts
- Opportunity
-
- Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Pre-Solicitation · HR001119S0035 · Posted Mar 1, 2019
- Contract value 51% obligated
-
- $500,000.00 Current, with exercised options
- $977,883.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02138, USA
- Research
- STTR Phase II
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$5,500 | |
| Funding Only Action | $5,500 | |
| Original award | $500,000 |
About this award
This is a $977,883 Firm Fixed Price STTR Phase II contract awarded by the Defense Advanced Research Projects Agency (DARPA) to General Biologics Inc., a small business. The contract is for the development of "Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems." This builds on a previous $225,000 STTR Phase I contract also awarded to General Biologics by DARPA for related "Patterned Responsive Cellular Therapies" research. General Biologics is collaborating with Harvard University and the Air Force Research Laboratory on this work, which aims to develop cellular therapy prototypes regulated by novel systems to address hypoxia in fighter pilots. The original solicitation was issued through DARPA's SBIR/STTR program, which seeks innovative research and development projects from small businesses and research institutions.
Quick answers
Who was awarded contract HR001121C0142?
HR001121C0142 was awarded to General Biologics Inc. by Defense Advanced Research Projects Agency (Department of Defense) on June 15, 2021.
How much is contract HR001121C0142 worth?
The government has obligated $500,000 on HR001121C0142. Its potential value, with all options, is $977,883.
Was contract HR001121C0142 competed?
The extent of competition for HR001121C0142 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award